HUTCHMED to Present HMPL-A580 IC50 1–10 nM Preclinical Data and Phase Ib/II Surufatinib Combo Updates at AACR
HUTCHMED will present preclinical HMPL-A580 data at AACR 2026 showing PI3K/PIKK payload IC50 of 1–10 nM and dose-dependent anti-tumor activity in EGFR+ xenograft models at 1–10 mg/kg. It will also reveal updated Phase Ib/II surufatinib plus sintilimib/capecitabine results in small bowel adenocarcinoma and exploratory Phase II surufatinib–AG pancreatic cancer data.
1. Preclinical HMPL-A580 Findings
HMPL-A580 demonstrated potent inhibition of PI3K and PIKK kinases with IC50 values of 1–10 nM and excellent selectivity across 418 kinases. In EGFR-expression tumor xenograft models, weekly IV doses of 1–10 mg/kg produced dose-dependent tumor growth suppression and robust apoptosis via rapid antibody conjugate internalization and payload release.
2. Updated Phase Ib/II Surufatinib Combo Results
The multicenter, single-arm Phase Ib/II trial of surufatinib plus sintilimib and capecitabine in previously treated metastatic small bowel adenocarcinoma and appendiceal carcinoma showed preliminary efficacy signals and safety consistent with known profiles, supporting further evaluation in this patient population.
3. Exploratory Phase II Surufatinib–AG Pancreatic Trial
An exploratory two-cohort Phase II study assessed sequential surufatinib combined with gemcitabine and nab-paclitaxel (AG) as first-line therapy for locally advanced or metastatic pancreatic ductal adenocarcinoma following AG induction, with initial findings slated for poster presentation.
4. Presentation Schedule
Key abstracts are scheduled for Poster Session: HMPL-A580 discovery on April 21 (PO.ET01.03), the surufatinib combo analysis on April 20 (PO.CT01.05), and the pancreatic AG study on April 20 (PO.CT01.05) at the AACR Annual Meeting in San Diego.